Navigation Links
Breakthrough Isolaz(TM) Acne Therapy Featured in U.S. News & World Report:
Date:6/10/2008

Aesthera Isolaz Therapy described as 'Advance Against Acne'

PLEASANTON, Calif., June 10 /PRNewswire/ -- Aesthera Corporation's Isolaz(TM) painless acne therapy has been featured in the June 9, 2008, issue of U.S. News & World Report, a leading national weekly news magazine. The publication describes Isolaz(TM) acne therapy as "an advance against acne" and reports that the Isolaz is the first treatment device FDA cleared to treat comedonal and pustular acne, in addition to mild to moderate, inflammatory acne and acne vulgaris.

Discussing clinical outcomes, the article explains the Isolaz(TM) system's effectiveness on patients of all ages, who have struggled with acne and have failed traditional therapies including topicals and antibiotics. Gilly Munavalli, MD, MHS, Director of Dermatology, Laser, and Veins Specialists of the Carolinas in Charlotte, NC and Clinical Instructor of Dermatology at Johns Hopkins University School of Medicine, notes that while the Isolaz also works on non-responders to traditional acne therapies, a greater benefit of the treatment is the rapid improvement relative to drugs.

The article describes a 22-year-old patient's struggle with acne and her 100% clinical, emotional and functional improvement post Isolaz(TM) treatments. Dermatologist Dale Isaacson, MD expresses great satisfaction with Isolaz system's efficacy noting that the device works in about 90% of his patients.

In addition to this breakthrough painless therapy for acne, Aesthera's Isolaz(TM) system is also FDA cleared to treat skin rejuvenation, including the treatment of vascular and pigmented lesions as well as hair removal on all skin types.

Prior to its coverage by U.S. News & World Report, Isolaz(TM) therapy has also been recently featured in the New York Times and Wall Street Journal. It has also been covered by Vogue, Elle, Allure, Shape, Bazaar, Self, and the June 2008 issues of Marie Claire and Family Circle, as a breakthrough
'/>"/>

SOURCE Aesthera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. A New Home for Medical Breakthroughs
2. Yales Scassellati gets Microsoft breakthrough research award for robotics
3. Innolife Pharma Inc. acquires rights to breakthrough in non-narcotic chronic pain treatment
4. Renowned ENT Specialist, Dr. Murray Grossan, Announces Medical Breakthrough on Snoring at PRI-MED Convention in Anaheim on May 15-17
5. Dental Convention to Highlight Latest Breakthroughs in Oral Health Treatments
6. Medical Breakthrough Reaches America
7. Tiny magnets offer breakthrough in gene therapy for cancer
8. New Breakthrough Treatment is Tough On Lice But Gentle On Kids
9. Key found to breakthrough drug for clot victims
10. Breakthrough Seating Technology, ergoSEET(TM), Now Available in Indianapolis
11. Breakthrough in birth-defect research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... July 06, 2015 , ... ... Associates has once again teamed up with Family Emergency Shelter Coalition (FESCO) and ... toward self-sufficiency. FESCO was created especially to provide emergency services and support for ...
(Date:7/6/2015)... Livonia, MI (PRWEB) , ... July 06, 2015 , ... ... Group has teamed up with Livonia Save Our Youth and announced a new charity ... young people in regards to alcohol and drug abuse. Livonia Save Our Youth is ...
(Date:7/6/2015)... ... July 06, 2015 , ... Dr. Lawrence Green is now ... patients. Kybella is a non-surgical method to dissolve fat cells and is ... to severe fat deposits under the chin, commonly known as a double chin. Dr. ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Diabetes affects ... help. More than 29 million Americans have diabetes, the majority of which are Type ... U.S. adults or more than one in three, have prediabetes (abnormally high blood sugar ...
(Date:7/5/2015)... ... 2015 , ... Security Life Insurance Company of America, a ... of PrimeStar Individual Dental Insurance. Beginning now, enhancements include the expansion of our ... (MAC) and usual, customary and reasonable (UCR). , Whether consumers are looking ...
Breaking Medicine News(10 mins):Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2
... 31 DaVita Inc. (NYSE: DVA ), a ... chronic kidney disease (CKD), today announced the DaVita Glomerular Filtration ... has been downloaded by patients across five continents and 24 ... list of countries where the application has been downloaded includes: ...
... stop menstruating, supplements boost vascular function, study finds ... folic acid supplementation improved vascular function in young ... caloric intake was lower than their energy output, ... acid may decrease cardiovascular risk and also improve ...
... 3 study reports improved survival for those with advanced disease, ... melanoma has shown promise in a new study. , Melanoma ... year-survival rates for local and metastatic melanoma are 65 percent ... in the United States will be diagnosed with melanoma and ...
... for advanced non-small cell malignancies , , SATURDAY, May 30 ... successful in safely slowing advanced non-small cell lung cancer ... a phase 3 trial involving 768 people with the ... dose of the bevacizumab (Avastin) saw the progression of ...
... researchers from the National Surgical Adjuvant Breast and ... in Pittsburgh reported today at the annual meeting ... in Orlando that use of the drug bevacizumab ... effective in prolonging disease-free survival (DFS) among patients ...
... failure represents the most common reason for hospitalisation in ... the first 24 hours after admission in around 50% ... associated with a more than 50% mortality and rehospitalisation ... from the Cardiology Department of the University of Brescia, ...
Cached Medicine News:Health News:DaVita's Kidney Calculator iPhone App Downloaded in 24 Countries 2Health News:DaVita's Kidney Calculator iPhone App Downloaded in 24 Countries 3Health News:Women Who Run May Benefit From Extra Folic Acid 2Health News:Experts Optimistic About Melanoma Vaccine 2Health News:Drug Combo Proves Powerful Against Lung Cancer 2Health News:Avastin Unsuccessful as Adjuvant Therapy in Setting of Stage II and III Colon Cancer but May Be Effective if Given for Longer Duration 2Health News:Avastin Unsuccessful as Adjuvant Therapy in Setting of Stage II and III Colon Cancer but May Be Effective if Given for Longer Duration 3Health News:Better treatment selection and improved therapies -- key to improving prognosis in acute HF 2
(Date:7/6/2015)... DUBLIN , June 29, 2015 ... the addition of the "Pharmaceutical Packaging Market in ... The pharmaceutical packaging market in North ... 5.31% over the period 2014-2019. International ... bodies on drug manufacturers, which in turn fuels adoption ...
(Date:7/6/2015)... July 6, 2015 E-QURE Corp (OTCQB: EQUR), ... live at VirtualInvestorConferences.com on July 9, 2015. ... http://tinyurl.com/e-qure-presentation This will be a ... ask the company questions in real-time - both in ... trade booth." If attendees are not able to join ...
(Date:7/6/2015)... ATLANTA , July 6, 2015 Celtaxsys, ... anti-inflammatory therapeutics, including those with rare and orphan inflammatory ... from the U.S. Food and Drug Administration (FDA) to ... drug candidate, acebilustat (CTX-4430), in adult CF patients in ... in Europe will be filed ...
Breaking Medicine Technology:North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 2North American Pharmaceutical Packaging Market 2015-2019 with Amcor, Bemis Healthcare Packaging, MeadWestvaco, Owens-Illinois & West Pharmaceutical Services Dominating 3E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
MultiWash Advantage is a versatile microplate washer engineered for reliability. It is designed for lab environments to help streamline their daily processes....
Synchron Hemoglobin A1c (HbA1c) utilizes two unique cartridges, Hb and A1c, to determine HbA1c concentration as a percentage of total hemoglobin....
... Monoclonal antibody method for HbA1c provides outstanding ... 99% agreement with the HPLC method(1) , ... a CV of 2.6%* means your results ... (NGSP) certified method, as recommended by the ...
The sole coagulation analyzer in the world that uses a unique dry reagent card....
Medicine Products: